1-13 of 13
Keywords: Sunitinib
Close
Sort by
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2019) 97 (3): 164–172.
Published Online: 13 June 2019
... and drug resistance in some cancers. However, the expression and biological role of miR-130b in renal cell carcinoma (RCC) remain poorly understood. This study aimed to examine the expression and functional role of miR-130b and to analyze the association between miR-130b and sunitinib resistance in RCC...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2017) 92 (3): 170–172.
Published Online: 12 November 2016
... refused systemic chemotherapy and received targeted therapies with sunitinib (37.5 mg/day, 5 patients) or the mammalian target of rapamycin (mTOR) inhibitor everolimus (10 mg/day, 1 patient) as the first-line treatment. We evaluated the drugs' toxicities and survival. The median age of the patients was 55...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2012) 82 (4): 189–196.
Published Online: 21 March 2012
... of treatment with sunitinib in the phase III study (n = 375, randomized to sunitinib) was 11 months (range <1–41) [ 1 ] and 6.9 months (range 1.4–34.6) in a global expanded access programme (n = 4,371) [ 9 ]. It should be noted that 68% of patients in the expanded access study had received prior cytokine...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2010) 78 (2): 130–140.
Published Online: 13 April 2010
... treatment. Sunitinib is approved for treatment of a GIST after disease progression on, or intolerance to, imatinib therapy. Progression may occur early or later on, in treatment and is determined by factors including initial GIST genotype and mutational status. GISTs with KIT exon 11 mutations appear...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2009) 77 (5): 257–271.
Published Online: 16 November 2009
... inhibitor class of novel targeted therapies, including sorafenib and sunitinib, has emerged as an important cause of HFS, with 10–28% of patients treated with sunitinib and 10–62% of patients treated with sorafenib reporting HFS. This review examines the epidemiology, clinical features, histopathology...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2008) 77 (2): 82–91.
Published Online: 13 July 2009
...Bohuslav Melichar For many years, therapy for metastatic renal cell carcinoma (mRCC) was limited to a single line of cytokine therapy with either interferon or interleukin-2. Relatively recently, the novel targeted agents bevacizumab, sorafenib, sunitinib and temsirolimus have each demonstrated...
Journal Articles
Journal Articles